Valeri Kraskovsky, MD
Pulmonary Disease · Buffalo, NYNPI 1396155529
Payments from drug & device makers
Across 166 payments — averaging $49.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$1K
- GSK$919
- Grifols USA, LLC$272
- Boehringer Ingelheim$268
- Pentax Of America, Inc.$212
- plus $1K from 21 others
What the payments were for
- Consulting fees$4656%
- Travel & lodging$7879%
- Food & beverage$4,02449%
- Education$3,01636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $4,135 |
| AstraZeneca | 31 | $1,172 |
| GSK | 37 | $919 |
| Grifols USA, LLC | 15 | $272 |
| Boehringer Ingelheim | 10 | $268 |
| Pentax Of America, Inc. | 5 | $212 |
| Sanofi | 6 | $182 |
| Noah Medical Corporation | 1 | $152 |
| Regeneron Healthcare Solutions, Inc. | 7 | $146 |
| Amgen | 7 | $132 |
| Mylan Specialty L.p. | 7 | $121 |
| Insmed, Inc. | 4 | $72 |
| Viatris Specialty LLC | 3 | $55 |
| Electromed, Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Novo Nordisk | 3 | $46 |
| Fujifilm Healthcare Americas Corporation | 2 | $43 |
| Galvanize Therapeutics, Inc | 1 | $34 |
| Baxter Healthcare | 2 | $33 |
| Vifor Pharma, Inc. | 1 | $31 |
| United Therapeutics Corporation | 1 | $28 |
| Pfizer | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Inogen, Inc. | 2 | $26 |
| Philips North America LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$725
- TAGRISSO$590
- NUCALA$364
- GALAXY$152
How this compares
$8,292 in reported general payments places this provider in the 75th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $327,071 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 250 | $261,127 |
| Dupixent PenDupilumab | 13 | $64,136 |
| Spiriva RespimatTiotropium Bromide | 85 | $61,406 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $51,229 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $43,304 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $34,215 |
| Spiriva HandihalerTiotropium Bromide | 26 | $19,124 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $18,815 |
| EliquisApixaban | 22 | $17,700 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $14,693 |
| Incruse ElliptaUmeclidinium Bromide | 42 | $14,116 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $13,408 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 246 | $8,673 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $7,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $268 | $407,292137 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $919 | $357,679441 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,172 | $64,637102 claims |
| PfizerEliquis | $28 | $17,70022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Buffalo
- Carla FrederickBuffalo$972K
- Nashat RabadiBuffalo$613K
- M Jeffery MadorBuffalo$408K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.